---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-179401"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-04-27T23:59:59+00:00"
generated_at: "2026-05-15T03:52:23.962758+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.95
calibrated_materiality_score: 0.95
confidence: "high"
source: SEC EDGAR
---

# Intellia announces positive Phase 3 HAELO results: 87% attack reduction, 62% attack-free; starts BLA for lonvo-z

## Summary
- Single dose of lonvo-z reduced HAE attacks by 87% vs placebo (mean monthly rate 0.26 vs 2.10, p<0.0001) over 6 months.
- 62% of lonvo-z patients were entirely attack-free and therapy-free vs 11% on placebo (p<0.0001); all key secondary endpoints met.
- No serious adverse events; all TEAEs mild/moderate; most common: infusion-related reactions, headache, fatigue.
- Rolling BLA submission to FDA initiated; potential U.S. launch in first half of 2027 if approved.
- Median follow-up 7.5 months; all lonvo-z patients remained long-term prophylaxis-free as of Feb 10, 2026 cutoff.

## SEC filing metadata
- accession: 0001193125-26-179401
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-04-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.95
- calibrated_materiality_score: 0.95
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/0001193125-26-179401-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526179401/d138980d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-179401
- JSON: https://secwatch.observer/filing/0001193125-26-179401.json
- Plain text: https://secwatch.observer/filing/0001193125-26-179401.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.